Ranatuerin-2VLb

General Information


DRACP ID  DRACP02623

Peptide Name   Ranatuerin-2VLb

Sequence  GIMDTIKGAAKDLAGQLLDKLKCKITKC

Sequence Length  28

UniProt ID  Not available

PubChem CID  Not available

Origin  Lithobates vaillanti

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HepG2 Hepatoblastoma Blastoma LC50=30 µM CytoTox 96 non-radiactive cytotoxicity assay  1 h 1

Hemolytic Activity  Huµan erythrocytes: HC50>200 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02623

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys23<--->Cys28

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C129H231N35O38S3

Absent amino acids  EFHNPRSVWY

Common amino acids  K

Mass  345848

Pl  9.51

Basic residues  6

Acidic residues  3

Hydrophobic residues  10

Net charge  3

Boman Index  -2254

Hydrophobicity  3.57

Aliphatic Index  108.21

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  125

Absorbance 280nm  4.63

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 19379837

Title  Purification of peptides with differential cytolytic activities from the skin secretions of the Central American frog, Lithobates vaillanti (Ranidae)

Doi 10.1016/j.cbpc.2009.04.003

Year  2009

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.